Publication:
Neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome: an important yet overlooked diagnosis in pediatric ataxia

Placeholder

Departments

School / College / Institute

Organizational Unit
SCHOOL OF MEDICINE
Upper Org Unit
Organizational Unit

Program

KU Authors

Co-Authors

Kebudi, Rejin

Editor & Affiliation

Compiler & Affiliation

Translator

Other Contributor

Date

Language

eng

Embargo Status

No

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Background. Opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare, immune-mediated neurological disorder, often associated with neuroblastoma (NB) in children. This study aimed to describe the clinical features, diagnostic challenges, treatment, and outcomes of pediatric patients with NB-associated OMAS. Methods. We retrospectively reviewed medical records of seven children diagnosed with NB-associated OMAS between November 1, 2015 and January 31, 2025. Data on demographics, clinical presentation, tumor characteristics, treatment protocols, relapses, and outcomes were collected. The Mitchell-Pike OMS Rating Scale was used to assess severity. Results. The cohort included four girls and three boys, aged 18-36 months (median 31). All had a history of infection and/or vaccination preceding symptom onset. Ataxia was the most common initial symptom (6/7, 85.7%), followed by behavioral disturbances and sleep disorders (5/7, 71.4% each). At presentation, opsoclonus was present in two patients, which was initially misdiagnosed as nystagmus. All but one patient had opsoclonus during the disease course. Neuroblastomas were located in abdominal (n=4), thoracic (n=1), and sacral (n=2) regions
all tumors measured <50 mm and were stage L1. First-line treatment included tumor resection, intravenous immunoglobulin, and corticosteroids. Three patients required second-line therapy (rituximab, cyclophosphamide, mycophenolate mofetil, or azathioprine). After a median follow-up of 40 months (range 26-64), four patients had no neurological sequelae
three had mild cognitive impairment. Conclusion. NB-associated OMAS may present with non-specific symptoms, leading to diagnostic delays. Early recognition, thorough tumor screening, and prompt immunotherapy may improve neurological outcomes. Clinicians should suspect NB in children presenting with ataxia and behavioral/sleep disturbances, even in the absence of opsoclonus or abnormal findings on initial imaging.

Source

Publisher

Turkish Journal of Pediatrics

Subject

Pediatrics

Citation

Has Part

Source

Turkish Journal of Pediatrics

Book Series Title

Edition

DOI

10.24953/turkjpediatr.2026.6821

item.page.datauri

Link

Rights

N/A

Copyrights Note

Creative Commons license

Except where otherwised noted, this item's license is described as N/A

Endorsement

Review

Supplemented By

Referenced By

Related Goal

0

Views

0

Downloads

View PlumX Details